Develops a brain-targeting Nurr1 agonist in CNS, suggesting potential neuroprotective benefits.
The ligand-sensing transcription factor nuclear receptor-related 1 (Nurr1), is thought to mediate neuroprotective activity and is implicated in various neurodegenerative diseases. Nurr1 ligands have been developed as tools to capture the receptor's potential in vitro and in vivo, but a dedicated brain-targeting agonist has been lacking. Here, we employed the scaffold of the dihydroorotate dehydrogenase (DHODH) inhibitor and strong Nurr1 activator vidofludimus to develop a descendant with a high brain-to-blood ratio. Scaffold-hopping from cyclopentene to thiophene, enhanced fluorination, and replacement of the carboxylic acid by an amide provided a highly potent, selective, and brain-penetrant Nurr1 agonist to study the effects of Nurr1 activation in the central nervous system (CNS).
No takes yet. Share an insight, caveat, or question.
Vietor et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: